Search - tctmd.com

Displaying 101 - 120 of 1566

Sort: Relevancy | Date

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

The ARIE-HM3 Trial

Podcast TCTMD Talking Points

The ARIE-HM3 Trial

March 13, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

News Daily News

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

March 04, 2024

Tirofiban May Cut Early Worsening After Acute Ischemic Stroke

News Conference News ISC 2024

Tirofiban May Cut Early Worsening After Acute Ischemic Stroke

February 13, 2024

Top Heart Failure News of 2023

News Daily News

Top Heart Failure News of 2023

January 05, 2024

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

News Daily News

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

January 04, 2024

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

Top Coronary Artery Disease News of 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

Aspirin Use Tied to Slower AAA Progression

News Daily News

Aspirin Use Tied to Slower AAA Progression

December 20, 2023

To Close Equity Gaps With New PCI-Capable Hospitals, Location Matters

News Daily News

To Close Equity Gaps With New PCI-Capable Hospitals, Location Matters

Michael O'Riordan

December 18, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

November 11, 2023

TCTMD’s Top 10 Most Popular Stories for October 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

November 01, 2023

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

Presentation TCT 2023

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

Presenter: Gaku Nakazawa

October 26, 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.